The earnings call presented a positive outlook with strong financial results, strategic growth in key business areas, and significant opportunities from new product clearances. However, challenges from divestiture impacts, foreign exchange losses, and tariff headwinds were acknowledged.

Company Guidance

During the Bioventus Inc. Second Quarter 2025 Earnings Conference Call, the company provided detailed guidance and insights into its financial performance and strategic priorities. Bioventus reported second-quarter revenue of $148 million, reflecting a 6% organic growth despite a 2% overall decline due to the divestiture of its Advanced Rehabilitation business. The company achieved adjusted earnings per share of $0.21, a 31% increase from the previous year, and an adjusted EBITDA margin of 23%. Bioventus reaffirmed its full-year 2025 guidance, expecting organic revenue growth between 6% and 8%, adjusted EBITDA of $112 million to $116 million, and EPS of $0.64 to $0.68. The company highlighted significant growth drivers, including strong double-digit growth in its Surgical Solutions and Restorative Therapies segments, and an anticipated acceleration in Pain Treatments in the second half of the year. Additionally, Bioventus emphasized the promising expansion opportunity presented by its recent 510(k) clearance for StimTrial and TalisMann in the peripheral nerve stimulation market, which is projected to grow over 20% annually in the U.S.

Strong Financial Performance

Bioventus reported second quarter revenue of $148 million, in line with expectations and reflecting a 6% organic growth despite challenging prior year comparisons. Adjusted earnings per share increased by 31% compared to the prior year, and the adjusted EBITDA margin of 23% exemplified stability and disciplined investment in key growth strategies.

Surgical Solutions Growth

The Surgical Solutions business delivered strong double-digit growth in ultrasonics, driven by enhanced precision and control for surgeons, reduced patient blood loss, and increased operating room efficiency.

Restorative Therapies Success

Exogen accelerated and achieved double-digit growth for the quarter, validating the approach to drive success across product categories with tighter focus, right strategy, targeted investments, and disciplined commercial execution.

510(k) Clearance for Chronic Pain Treatment

Bioventus received 510(k) clearance for StimTrial and TalisMann for peripheral nerve stimulation, opening a significant growth opportunity in the fast-growing PNS market, expected to exceed $500 million by 2029.

Cash Flow and Debt Management

Cash flow from operations totaled $26 million, an increase of $11 million compared to the prior year. The company expects to nearly double cash flow from operations compared to 2024, and refinanced its credit facility with benefits like reduced interest rates and extended maturity.

Bioventus (BVS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BVS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.11 / -	0.06	―	―	―
Aug 06, 2025	2025 (Q2)	0.16 / 0.21	0.19	10.53% (+0.02)
May 06, 2025	2025 (Q1)	0.03 / 0.08	0.07	14.29% (<+0.01)
Mar 11, 2025	2024 (Q4)	0.08 / 0.15	0.07	114.29% (+0.08)
Nov 05, 2024	2024 (Q3)	0.02 / 0.06	0.05	20.00% (<+0.01)
Aug 06, 2024	2024 (Q2)	0.07 / 0.19	0.14	35.71% (+0.05)
May 07, 2024	2024 (Q1)	-0.07 / 0.07	-0.26	126.92% (+0.33)
Mar 12, 2024	2023 (Q4)	0.02 / 0.07	-0.06	216.67% (+0.13)
Nov 07, 2023	2023 (Q3)	-0.02 / 0.05	0.08	-37.50% (-0.03)
Aug 08, 2023	2023 (Q2)	>-0.01 / 0.14	0.1	40.00% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BVS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$6.14	$7.29	+18.73%
May 06, 2025	$7.03	$6.20	-11.81%
Mar 11, 2025	$8.76	$10.80	+23.29%
Nov 05, 2024	$13.71	$11.48	-16.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bioventus (BVS) report earnings?

Bioventus (BVS) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Bioventus (BVS) earnings time?

Bioventus (BVS) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BVS EPS forecast?

BVS EPS forecast for the fiscal quarter 2025 (Q3) is 0.11.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing